Dr. Tracey Evans on Chemotherapy for the Elderly Patient

Video

Tracey Evans, MD, Associate Professor of Clinical Medicine University of Pennsylvania Health System, discusses how to determine which patients will benefit from chemotherapy.

Tracey Evans, MD, Associate Professor of Clinical Medicine University of Pennsylvania Health System, discusses how to determine which patients will benefit from chemotherapy.

The elderly, who are defined as those aged 65 or older, have historically not been considered good candidates for chemotherapy, Evans says. Because of this, they are often denied chemotherapy or given more gentle chemotherapy regimen.

Evans says more recent studies have shown that physiologic age is more important than chronological age. While elderly patients tend to experience more toxicities with chemotherapy​, they see the same survival benefit from platinum-based doublet chemotherapy as non-elderly patients.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine